New Data Supports Cortisol Hypothesis
Filed with ASX · · 2 pages · English
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- December 2017 Quarterly Report
- Prospectus
- Early Efficacy & Safety Data Planned for XanADu Trial
- Placement Fully Funds Completion of XanADu Alzheimers Trial
- R&D Rebate Received Totalling $1.22 Million
Later from Actinogen Medical
- Strong Recruitment Progress in Alzheimers Trial
- Mid-Way Point Reached in Landmark Alzheimers Trial - XanADu
- March 2018 Quarterly Report
- XanADu Interim Analysis-Continuation Without Change
- $15m Placement Completed-Including US Cornerstone Investor
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical